Clinical Trial Update: A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence [Phase 2]

View source ↗

Summary

Phase 2 randomized, placebo-controlled trial of EG017 in female patients with stress urinary incontinence has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stress Urinary Incontinence

Drugs mentioned

• EG017

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Stress Urinary Incontinence | Phase 2 | Status: COMPLETED